Activin and Inhibin

KW-8232, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2In VitroKW-8232 is an anti-osteoporotic agent. KW-8232 reduces the biosynthesis of PGE 2 in mouse osteoblastic cells. KW-8232 possesses anti-viral activity

KW-8232, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2In VitroKW-8232 is an anti-osteoporotic agent. KW-8232 reduces the biosynthesis of PGE 2 in mouse osteoblastic cells. KW-8232 possesses anti-viral activity

KW-8232 free base, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2In VitroKW-8232 is an anti-osteoporotic agent. KW-8232 reduces the biosynthesis of PGE 2 in mouse osteoblastic cells. KW-8232 possesses anti-viral

KWCN-41 is a selective and efficient inhibitor of RIPK1 kinase with an IC 50 value of 88 nM. KWCN-41 specifically inhibits cell necrosis but does not inhibit apoptosis . KWCN-41 also has anti-inflammatory effectsIn VitroKWCN-41 (10, 50, 250 nM: 1 h)

KWCN-41 is a selective and efficient inhibitor of RIPK1 kinase with an IC 50 value of 88 nM. KWCN-41 specifically inhibits cell necrosis but does not inhibit apoptosis . KWCN-41 also has anti-inflammatory effectsIn VitroKWCN-41 (10, 50, 250 nM: 1 h)

KWCN-41 is a selective and efficient inhibitor of RIPK1 kinase with an IC 50 value of 88 nM. KWCN-41 specifically inhibits cell necrosis but does not inhibit apoptosis . KWCN-41 also has anti-inflammatory effectsIn VitroKWCN-41 (10, 50, 250 nM: 1 h)

KWCN-41 is a selective and efficient inhibitor of RIPK1 kinase with an IC 50 value of 88 nM. KWCN-41 specifically inhibits cell necrosis but does not inhibit apoptosis . KWCN-41 also has anti-inflammatory effectsIn VitroKWCN-41 (10, 50, 250 nM: 1 h)

KWCN-41 is a selective and efficient inhibitor of RIPK1 kinase with an IC 50 value of 88 nM. KWCN-41 specifically inhibits cell necrosis but does not inhibit apoptosis . KWCN-41 also has anti-inflammatory effectsIn VitroKWCN-41 (10, 50, 250 nM: 1 h)

KZR-504 is a highly selective inhibitor of immunoproteasome low molecular mass polypeptide 2 (LMP2) , with IC 50 s of 51 nM, 4.274 μM for LMP2 and LMP7, respectively. KZR-504 is of interest for the treatment of autoimmune diseaseIn VivoEvaluating

KZR-504 is a highly selective inhibitor of immunoproteasome low molecular mass polypeptide 2 (LMP2) , with IC 50 s of 51 nM, 4.274 μM for LMP2 and LMP7, respectively. KZR-504 is of interest for the treatment of autoimmune diseaseIn VivoEvaluating

KZR-504 is a highly selective inhibitor of immunoproteasome low molecular mass polypeptide 2 (LMP2) , with IC 50 s of 51 nM, 4.274 μM for LMP2 and LMP7, respectively. KZR-504 is of interest for the treatment of autoimmune diseaseIn VivoEvaluating

KZR-504 is a highly selective inhibitor of immunoproteasome low molecular mass polypeptide 2 (LMP2) , with IC 50 s of 51 nM, 4.274 μM for LMP2 and LMP7, respectively. KZR-504 is of interest for the treatment of autoimmune diseaseIn VivoEvaluating